Yarrow Bioscience Statistics
Want to see YARW full AI Analyst Report?
Yarrow Bioscience (YARW) Stock Statistics & Valuation Metrics
Total Valuation
Yarrow Bioscience has a market cap or net worth of $170.35M. The enterprise value is $625.88K.
- Market Cap
- $170.35M
- Enterprise Value
- $625.88K
Share Statistics
Yarrow Bioscience has 9,437,693 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 9,437,693
- Owned by Insiders
- 16.35%
- Owned by Institutions
- 19.12%
Financial Efficiency
Yarrow Bioscience’s return on equity (ROE) is -0.95 and return on invested capital (ROIC) is -107.15%.
- Return on Equity (ROE)
- -0.95
- Return on Assets (ROA)
- -0.88
- Return on Invested Capital (ROIC)
- -107.15%
- Return on Capital Employed (ROCE)
- -1.07
- Revenue Per Employee
- 57.00K
- Profits Per Employee
- -2.65M
- Employee Count
- 10
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Yarrow Bioscience is -0.83. Yarrow Bioscience’s PEG ratio is -0.01.
- PE Ratio
- -0.83
- PS Ratio
- 376.32
- PB Ratio
- 0.76
- Price to FCF
- -10.71
- Price to Operating Cash Flow
- -0.99
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Yarrow Bioscience had revenue of 570.00K and earned -26.48M in profits. Earnings per share was -30.96.
- Revenue
- 570.00K
- Gross Profit
- 547.00K
- Operating Income
- -29.75M
- Pretax Income
- -26.73M
- Net Income
- -26.48M
- EBITDA
- -26.71M
- Earnings Per Share (EPS)
- -30.96
Cash Flow
In the last 12 months, operating cash flow was -99.79M and capital expenditures 0, giving a free cash flow of -99.79M billion.
- Operating Cash Flow
- -99.79M
- Free Cash Flow
- -99.79M
- Free Cash Flow per Share
- -19.74
Dividends & Yields
Yarrow Bioscience pays an annual dividend of $20.10, resulting in a dividend yield of 102.39%
- Dividend Per Share
- $20.10
- Dividend Yield
- 102.39%
- Payout Ratio
- -131.99%
- Free Cash Flow Yield
- -9.27%
- Earnings Yield
- -111.08%
Stock Price Statistics
- Beta
- 1.63
- 52-Week Price Change
- 11.44%
- 50-Day Moving Average
- 22.54
- 200-Day Moving Average
- 21.88
- Relative Strength Index (RSI)
- 51.54
- Average Volume (3m)
- 139.95K
Important Dates
Yarrow Bioscience upcoming earnings date is ―, Before Open (Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- Jul 24, 2026
Financial Position
Yarrow Bioscience as a current ratio of 12.53, with Debt / Equity ratio of 0.00%
- Current Ratio
- 12.53
- Quick Ratio
- 12.53
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.90
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Yarrow Bioscience has paid 4,000 in taxes.
- Income Tax
- 4,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Yarrow Bioscience EV to EBITDA ratio is -8.48, with an EV/FCF ratio of -9.43.
- EV to Sales
- 331.37
- EV to EBITDA
- -8.48
- EV to Free Cash Flow
- -9.43
- EV to Operating Cash Flow
- -9.43
Balance Sheet
Yarrow Bioscience has $268.86M in cash and marketable securities with $0.00 in debt, giving a net cash position of $268.86M billion.
- Cash & Marketable Securities
- $268.86M
- Total Debt
- $0.00
- Net Cash
- $268.86M
- Net Cash Per Share
- $28.49
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 97.51%, with operating margin of -4134.65%, and net profit margin of -3881.54%.
- Gross Margin
- 97.51%
- Operating Margin
- -4134.65%
- Pretax Margin
- -3914.11%
- Net Profit Margin
- -3881.54%
- EBITDA Margin
- -3909.34%
- EBIT Margin
- -3914.11%
Analyst Forecast
The average price target for Yarrow Bioscience is $60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $60.00
- Price Target Upside
- 205.65% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -40.27%
- EPS Growth Forecast
- 60.99%
Scores
- Smart Score
- 6
- AI Score
- 45
